Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.

Tiraboschi G, Papp K, Bieber T, Weidinger S, Beck L, Lee CH, O'Malley JT, Yen K, Bernigaud C, Fabre D, Hurbin F

DOI: 10.1002/psp4.70121
Published: 2025 Dec
Container: CPT: pharmacometrics & systems pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/psp4.70121,
  title = {Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.},
  author = {Tiraboschi G and Papp K and Bieber T and Weidinger S and Beck L and Lee CH and O'Malley JT and Yen K and Bernigaud C and Fabre D and Hurbin F},
  year = {2025},
  journal = {CPT: pharmacometrics \& systems pharmacology},
  doi = {10.1002/psp4.70121},
  url = {https://doi.org/10.1002/psp4.70121}
}

RIS

TY  - JOUR
TI  - Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.
AU  - Tiraboschi G
AU  - Papp K
AU  - Bieber T
AU  - Weidinger S
AU  - Beck L
AU  - Lee CH
AU  - O'Malley JT
AU  - Yen K
AU  - Bernigaud C
AU  - Fabre D
AU  - Hurbin F
PY  - 2025
JO  - CPT: pharmacometrics & systems pharmacology
DO  - 10.1002/psp4.70121
UR  - https://doi.org/10.1002/psp4.70121
ER  -

APA

G, T., K, P., T, B., S, W., L, B., CH, L., JT, O., K, Y., C, B., D, F., & F, H. (2025). Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.. CPT: pharmacometrics & systems pharmacology. https://doi.org/10.1002/psp4.70121

Source records

pubmed · retrieved 2026-09-26T19:34:25.769Z